BACKGROUND: There is no standard therapy for patients with transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). This study examined whether evaluating the tumor effect (TE) at 1 week after TACE was useful for predicting refractoriness to TACE. METHODS: We performed a historical cohort study involving 54 patients and 119 tumors. TE was evaluated at 1 week and 3 months after TACE, and an overall evaluation was also performed at 3 months based on the response evaluation criteria in cancer of the liver. RESULTS: Among 45 tumors evaluated as TE2 at 1 week, 43 tumors (95.6%) were classified as TE1 or TE2 at 3 months. Of the 24 patients whose tumors were categorized as TE2 at 1 week, none achieved a complete or partial response. CONCLUSIONS: Evaluating the TE at 1 week after TACE is useful for the early diagnosis of TACE-refractory HCC and allows alternative treatment options, such as sorafenib, to be employed before the disease progresses.
BACKGROUND: There is no standard therapy for patients with transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). This study examined whether evaluating the tumor effect (TE) at 1 week after TACE was useful for predicting refractoriness to TACE. METHODS: We performed a historical cohort study involving 54 patients and 119 tumors. TE was evaluated at 1 week and 3 months after TACE, and an overall evaluation was also performed at 3 months based on the response evaluation criteria in cancer of the liver. RESULTS: Among 45 tumors evaluated as TE2 at 1 week, 43 tumors (95.6%) were classified as TE1 or TE2 at 3 months. Of the 24 patients whose tumors were categorized as TE2 at 1 week, none achieved a complete or partial response. CONCLUSIONS: Evaluating the TE at 1 week after TACE is useful for the early diagnosis of TACE-refractory HCC and allows alternative treatment options, such as sorafenib, to be employed before the disease progresses.
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Brian S Letzen; Rohil Malpani; Milena Miszczuk; Quirina M B de Ruiter; Christopher W Petty; Irvin Rexha; Nariman Nezami; Fabian Laage-Gaupp; MingDe Lin; Todd R Schlachter; Julius Chapiro Journal: Clin Imaging Date: 2021-05-18 Impact factor: 2.420
Authors: Kenya Yamanaka; Marius Petrulionis; Shibo Lin; Chao Gao; Uwe Galli; Susanne Richter; Susanne Winkler; Philipp Houben; Daniel Schultze; Etsuro Hatano; Peter Schemmer Journal: Cancer Med Date: 2013-10-22 Impact factor: 4.452
Authors: Joonho Jeong; Jung Gu Park; Kwang Ill Seo; Ji Hyun Ahn; Jae Chun Park; Byung Cheol Yun; Sang Uk Lee; Jin Wook Lee; Jong Hyouk Yun Journal: Medicine (Baltimore) Date: 2021-07-09 Impact factor: 1.889